BMJ Editorials: September 2013

What is the future of hospitals?    Mark Newbold

What to do about unsafe medicines?         Gillian J Buckley, Jim E Riviere, and Lawrence O Gostin

Descriptions of non-pharmacological interventions in clinical trials A Cook, L Douet, and Isabelle Boutron

The word “cancer”: how language can corrupt thought BK Dunn, Sudhir Srivastava, and Barnett S Kramer

Secondary prevention of venous thromboembolism      Sam Schulman and James Douketis

BMJ topics: August 2013

Here’s a selection of content from this month’s BMJ – click on this link if you want to read the full issue.

Feature

Patient information leaflets: “a stupid system”    Margaret McCartney

The growth of medical marijuana  Owen Dyer

Sharing data from clinical trials: where we are and what lies ahead  Elizabeth Loder

News

GPs taking on out of hours work face higher indemnity fees   Gareth Iacobucci

New dementia targets are proposed for GPs in next year’s QOF    Adrian O’Dowd

Don’t call low risk lesions cancer, experts say   Michael McCarthy

Opposition to abortion is growing in Southern and Midwestern US states    Michael McCarthy

Doctors should have to be accredited to support whiplash claims, say MPs    Ingrid Torjesen

Rescue boards are set up in England to deal with “significant deterioration” in A&E departments Matthew Limb

Editorials

Physician Payment Sunshine Act  José G Merino

The Liverpool care pathway: a cautionary tale  Katherine E Sleeman and Emily Collis

Medical savings accounts: Singapore’s non-solution to healthcare costs  Martin McKee and Reinhard Busse

India’s new policy to protect research participants   Jeremy Sugarman, Anant Bhan et al

Government’s plans for universal health checks for people aged 40-75   Felicity Goodyear-Smith

Leading healthcare in London: time for a radical response?   Naomi Fulop and Rosalind Raine

European Radiology, July 2012; Imaging vascular function for early stage clinical trials …

Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging
Citation: European Radiology, July 2012, vol./is. 22/7(1451-1464), 0938-7994;1432-1084 (July 2012)
Author(s): Leach M.O.; Morgan B.; Tofts P.S.; Buckley D.L.; Huang W.; Horsfield M.A.; Chenevert T.L.; Collins D.J.; Jackson A.; Lomas D.; Whitcher B.; Clarke L.; Plummer R.; Judson I.; Jones R.; Alonzi R.; Brunner T.; Koh D.M.; Murphy P.; Waterton J.C.; Parker G.; Graves M.J.; Scheenen T.W.J.; Redpath T.W.; Orton M.; Karczmar G.; Huisman H.; Barentsz J.; Padhani A.

Abstract: Many therapeutic approaches to cancer affect the tumour vasculature, either indirectly or as a direct target. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has become an important means of investigating this action, both pre-clinically and in early stage clinical trials. For such trials, it is essential that the measurement process (i.e. image acquisition and analysis) can be performed effectively and with consistency among contributing centres. As the technique continues to develop in order to provide potential improvements in sensitivity and physiological relevance, there is considerable scope for between-centre variation in techniques. A workshop was convened by the Imaging Committee of the Experimental Cancer Medicine Centres (ECMC) to review the current status of DCEMRI and to provide recommendations on how the technique can best be used for early stage trials. This review and the consequent recommendations are summarised here. Key Points Tumour vascular function is key to tumour development and treatment Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can assess tumour vascular function Thus DCE-MRI with pharmacokinetic models can assess novel treatments Many recent developments are advancing the accuracy of and information from DCE-MRI Establishing common methodology across multiple centres is challenging and requires accepted guidelines.

European Society of Radiology 2012.

Publication Type: Journal: Article
Source: EMBASE